by lythamcorp | Dec 17, 2024 | Reviva Pharma News
CUPERTINO, Calif., Dec. 16, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
by lythamcorp | Dec 16, 2024 | Reviva Pharma News
CUPERTINO, Calif., Dec. 16, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
by lythamcorp | Dec 16, 2024 | Reviva Pharma News
– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and discontinuation – – Full data set from...
by lythamcorp | Dec 16, 2024 | Reviva Pharma News
– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and discontinuation – – Full data set from...
by lythamcorp | Dec 11, 2024 | PolyPid, PolyPid News
PETACH TIKVA, Israel, Dec. 11, 2024 — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with...